Microsoft word - aau release 20090714 final.doc

UNIVERSITIES ALLIED FOR ESSENTIAL MEDICINES

July 14, 2009
Contact: Eleanor Blume
Phone: 781.640.7750
Email: eleanor.blume@gmail.com

For Immediate Release

STUDENT GROUPS AND CONSUMER ADVOCATES DEMAND
WITHDRAWAL OF UNIVERSITY SUPPORT FOR HARMFUL LEGISLATION
Legislation Would Delay Affordable Medicines in the United States and Abroad BERKELEY – Today, the American Medical Student Association, Essential Action, and Universities Al ied for Essential Medicines (UAEM) joined together in demanding that the Association of American Universities (AAU) withdraw its endorsement of H.R. 1548, the “Pathway for Biosimilars Acts” in a letter sent to AAU President Robert Berdahl.1 AAU has so far resisted cal s to rescind its support of the unjustifiably long twelve years of brand exclusivity permitted by the bil . Such a monopoly period would delay the introduction of generic versions of biologics (cal ed fol ow-on biologics or biosimilars) which include vaccines as well as life-saving cancer, arthritis, and diabetes drugs, keeping medicine prices high and out of the hands of many consumers in the U.S. and developing countries. The groups are also asking Congress to include a reasonable period of exclusivity that will safeguard affordable access. Small molecule medicines such as Prilosec have exclusivity Economic analyses have repeatedly refuted the AAU’s claim, repeated by the Biotechnology Industry Organization (BIO), that twelve years of exclusivity are needed for sufficient cost recovery to sustain innovation. A recent paper by the Federal Trade Commission estimates that the introduction of fol ow-on biologics would generate tremendous savings on the $40.3 bil ion U.S. consumers spend on biologics each year, some of which cost tens of thousands of dol ars per course of treatment.2 The extended exclusivity terms in H.R. 1548 and several other legislative proposals would maximize royalties from biologics patents licensed by universities, which are non-profit institutions, at the cost of access. “AAU’s support for H.R. 1548 truly threatens the core identity of universities as non-profit organizations dedicated to the creation and dissemination of knowledge for the public good,” said Ethan Guil en, Executive Director of UAEM. Each year the federal government – that is, U.S. taxpayers – provides bil ions of dol ars in research support, accounting for more than 60% of university research budgets. It is unconscionable for federal y funded universities, represented by AAU, to so cal ously 1 http://www.aau.edu/WorkArea/DownloadAsset.aspx?id=9016 2 See Federal Trade Commission, Emerging Health Care Issues: Fol ow-On Biologic Drug Competition, June 2009. Available at: http://www.ftc.gov/opa/2009/06/biologics.shtm and Henry Grabowski, Outlook: Fol ow-on biologics: data exclusivity and the balance between innovation and competition. Nature Reviews Drug Discovery 7, 479-488 (June 2008). Available at: http://www.nature.com/nrd/journal/v7/n6/ful /nrd2532.html. UNIVERSITIES ALLIED FOR ESSENTIAL MEDICINES

obstruct taxpayer access to their life-saving therapeutics. This contradiction is even more
poignant at a time when individuals and the federal government struggle to control bal ooning healthcare costs. An excessive term of exclusivity wil further impede affordable access to critical vaccines, including potential y those for pandemic flu outbreaks. For those ten mil ion people, primarily in developing countries, who die every year because they do not have access to basic medicine, the exclusivity terms in H.R. 1548 wil further exacerbate the access gap by delaying the onset of lower-cost fol ow-on biologics, including critically needed vaccines. Developing a process for getting biosimilars to market is a critical step to furthering access to affordable medicines. However, in regards to exclusivity terms, universities must show courage in adopting evidence-based stances that benefit society, and not simply act as echo chambers for PhRMA and BIO priorities. Alternate proposals currently being considered include the “Promoting Innovation and Access to Life-Saving Medicine Act” introduced in both the House (H.R. 1427) and the Senate (S.726), proposing a five year exclusivity term, and several proposals for a seven year exclusivity term. Which one of these competing proposals -- 12 to 14 years or five to seven years -- succeeds wil shape access to life-saving medicines in the U.S. and abroad and the ability of our health system to control bal ooning The letter to the AAU is available at: http://www.essentialmedicine.org/uaem-amsa-and- essential-action-demand-aau-rescind-support-of-excessive-data-exclusivity/
About UAEM

Universities Al ied for Essential Medicines (UAEM) is a coalition of students at over 40 top research institutions across the United States, Canada, the United Kingdom, and Germany. UAEM’s mission is to ensure that people in developing countries have access to medicines developed in universities and that university medical research addresses the needs of the majority of the world’s population. As an organization which values innovation, we work to empower students to find new ways to improve access to health throughout the world. www.essentialmedicine.org
About the American Medical Student Association
The American Medical Student Association (AMSA), with more than a half-century history of medical student activism, is the oldest and largest independent association of physicians- in-training in the United States. Founded in 1950, AMSA is a student-governed, non-profit organization committed to representing the concerns of physicians-in-training. With more than 62,000 members, including medical and premedical students, residents and practicing physicians, AMSA is committed to improving medical training as wel as advancing the profession of medicine. AMSA focuses on four strategic priorities, including advocating for quality, affordable health care for al , global health equity, enriching medicine through diversity and professional integrity, development and student wel being. To learn more about AMSA, our strategic priorities, or joining the organization, please visit us online at UNIVERSITIES ALLIED FOR ESSENTIAL MEDICINES

About Essential Action
Essential Action is a public health and corporate accountability group located in

Source: http://archive.uaem.org/sites/default/files/archive/aau-release-20090714-final.pdf

Http://www.ashp.org/news/showarticle.cfm?cfid=1007935&cftoken=8

Antineoplastics Declared Occupational Hazard [May 15, 2004, AJHP News] BETHESDA, MD, 07 May 2004 — A federal science-based group recently urged health care workers, employers, and safety professionals to take immediate action to reduce the risks from a "newly identified" occupational hazard: exposure to antineoplastics and other The alert, issued i

Titolo

CONSIDERAZIONI SULL’USO DEGLI IMMUNOSOPPRESSORI EQUIVALENTI DOPO TRAPIANTO D’ORGANO SOLIDO Introduzione I pazienti portatori di un trapianto d’organo solido (rene, fegato, cuore, polmone, pancreas, intestino) devono assumere quotidianamente farmaci immunosoppressori per la prevenzione del L’uso di questi farmaci ha rappresentato, e rappresenta tutt’ora, uno degli

Copyright © 2014 Articles Finder